The project includes the teams from Professor Ksenia Kastanenka (HMS) and Professor
Positive results from these studies will strengthen the case for clinical trials of GT-002 in cognitive dysfunction, particularly in Alzheimer's disease patients.
The drug candidate GT-002 is a selective GABAA receptor modulator with the potential to improve the treatment of several common psychiatric disorders. The results from the Phase 1 clinical trials show that the drug candidate is safe and well tolerated and has excellent pharmacokinetic properties in healthy individuals receiving single, as well as repeated doses of GT-002. A clinical study to explore the interaction of GT-002 with GABAA receptors and how it affects human brain activity will be initiated when the medical authority in
VD
mrw@gabather.com
https://news.cision.com/gabather-ab/r/gabather-ab-invited-by-the-alzheimer-s-drug-discovery-foundation--usa-to-submit-a-grant-application-,c3529543
(c) 2022 Cision. All rights reserved., source